JDD Buzz Series | Skin of Color Representation in Pre-Clerkship Dermatology Curriculum
Medical school dermatology curriculum is known for its lack of representation of images of skin of color. A letter to the editor published in the July Journal of Drugs in Dermatology shows the effects on diagnostic accuracy, perception, and confidence when one medical school took action to make its pre-clerkship dermatology curriculum more diverse.
I interviewed authors Dahyeon (Esther) Kim, a …
Medical school dermatology curriculum is known for its lack of representation of images of skin of color. A letter to the editor published in the July Journal of Drugs in Dermatology shows the effects on diagnostic accuracy, perception, and confidence when one medical school took action to make its pre-clerkship dermatology curriculum more diverse.
I interviewed authors Dahyeon (Esther) Kim, a … 
At the most recent Skin of Color Update, we had the honor to learn about pediatric inflammatory skin conditions from the renowned Dr. Candrice Heath, triple board-certified dermatologist and Associate Professor at the Howard University Department of Dermatology and Dr. Brandi Kenner-Bell, Assistant Professor of Dermatology and Pediatrics at the Northwestern University Feinberg School of Medicine.
… 
June and July mark a major milestone—you’re wrapping up intern year and are finally starting dermatology residency. You’ve survived night shifts, rapid responses, and figuring out how to juggle clinical demands like a pro. Just when you felt like you were getting the hang of things… you’re resetting the clock and diving headfirst into a specialty that sometimes feels like an entirely dif … 
The July 2025 issue of the Journal of Drugs in Dermatology brings together another outstanding selection of articles, offering cutting-edge insights and real-world strategies across a diverse range of dermatology topics. This month’s editor’s highlights spotlight innovative approaches to photoprotection in melasma and photodamage, emerging non-pharmaceutical solutions for fem … 
Secukinumab is a recombinant human monoclonal immunoglobulin IgG1κ antibody that selectively targets interleukin-17A (IL-17A), a key effector cytokine in the Th17 pathway implicated in the pathogenesis of psoriasis. With its high target specificity, rapid onset, sustained efficacy, and favorable safety profile, secukinumab has become a mainstay in the treatment of psoriasis and other inflammatory …